sglt2 inhibitor vs glp 1 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application Cardiovascular benefits of SGLT2 inhibitors

Although GLP-1 RAs are widely used to treat T2D and obesity, research examining their interactions with resident gut microbial communities in humans remains limited

The primary mechanisms of action include: Enhancing insulin secretion from pancreatic beta cells in a glucose-dependent manner, which helps lower blood glucose levels without causing excessive hypoglycaemia Suppressing glucagon release from pancreatic alpha cells, reducing hepatic glucose production Slowing gastric emptying , which prolongs the feeling of fullness after meals Acting on appetite centres in the brain , particularly the hypothalamus, to reduce hunger and food intake Most GLP-1 receptor agonists are administered via subcutaneous injection, with dosing frequencies ranging from once daily to once weekly depending on the specific formulation

A meta-analysis of antioxidant supplementation in individuals with obesity has shown beneficial effects on reducing body mass index (BMI), waist circumference (WC), fasting blood glucose, and improving markers of oxidative stress and inflammation compared to placebo [84]

Patients may be more stringently screened, particularly for thyroid nodules/cancer in patients receiving GLP-1 receptor agonists

Association of semaglutide with tobacco use disorder in patients with type 2 diabetes: Target trial emulation using real-world data

Just in the past year, there have been more than 36 psychedelic health-related initiatives introduced across more than a dozen states, really representing unprecedented legislative activity